

Immune Responses to Dengue and Sepsis

NCT07040202

| | |
|------------|------------------------------|
| Status | RECRUITING |
| Sponsor | Institut Pasteur du Cambodge |
| Enrollment | 240 participants |

Key Eligibility Criteria

Inclusion (6)

- Patients with dengue-like illness:
 - Patients presenting with dengue-like symptoms for a duration of maximum 72h before inclusion. Dengue-like symptoms include: presentation with oral temperature $\geq 38^{\circ}\text{C}$ AND at least two of the following symptoms suggestive of dengue-like illness: headache, retro-orbital pain, myalgia, joint pain, rash, any bleeding symptoms, nausea or vomiting, lethargy or restlessness, abdominal pain, liver enlargement
 - Sepsis patients:
 - Patients admitted for less than 48 hours with a primary diagnosis of sepsis as per treating team AND have blood cultures ordered AND on empiric antibiotics due to concern for bacterial infection.
 - Healthy controls:
- ... and 1 more (see full listing online)

Exclusion (7)

- For biobanking purposes, children less than 2 years of age, and individuals who are pregnant, pregnant within the last 90 days, and/or breastfeeding are excluded due to restrictions on the blood volumes and the repeated sampling times.
 - Individuals that do not provide informed consent will not be included for the study.
 - Severe/chronic/recurrent pathological conditions: clinically significant autoimmune disease or immunodeficiency (including history of organ transplant), haematologic disorders, cardiac diseases, diabetes, cancer, HIV, chronic hepatic or renal insufficiency.
 - Chronic administration (defined as more than 14 days) of immunosuppressants or other immune-modifying drugs within the 6 months prior to the inclusion. For corticosteroids, this will mean a dose equivalent to 20 mg/day of prednisone or equivalent for ≥ 2 weeks (inhaled and topical steroids allowed)
 - Chronic administration of NSAIDs, including aspirin: prolonged intake (≥ 2 weeks) within 6 months before study or any intake within the 7 days preceding sampling [exception for low dose aspirin: maximum 250mg/daily]
- ... and 2 more (see full listing online)

Locations (3 total)

Kampong Speu District Referral Hospital, Kampong Speu, Cambodia
International Center of Excellence in Research Cambodia, Phnom Penh, Cambodia
Preah Kossamak Hospital, Phnom Penh, Cambodia

<https://clinicaltrials.gov/study/NCT07040202>

DISCLAIMER: This document is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before enrolling in any clinical trial. Information may not be up to date — verify details at ClinicalTrials.gov. Generated by ClinicalTrialsFinder.org.